Related Experiment Video
Updated: Oct 7, 2025

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays
Published on: September 20, 2024
Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features
Foad Rommasi1, Mohammad Javad Nasiri2, Mehdi Mirsaeidi3
1Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran. f.ramasi@mail.sbu.ac.ir.
Abstract:
The novel coronavirus pandemic has emerged as one of the significant medical-health challenges of the current century. The World Health Organization has named this new virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the first detection of SARS-CoV-2 in November 2019 in Wuhan, China, physicians, researchers, and others have made it their top priority to find drugs and cures that can effectively treat patients and reduce mortality rates. The symptoms of Coronavirus Disease 2019 (COVID-19) include fever, dry cough, body aches, and anosmia. Various therapeutic compounds have been investigated and applied to mitigate the symptoms in COVID-19 patients and cure the disease. Degenerative virus analyses of the infection incidence and COVID-19 have demonstrated that SARS-CoV-2 penetrates the pulmonary alveoli's endothelial cells through Angiotensin-Converting Enzyme 2 (ACE2) receptors on the membrane, stimulates various signaling pathways and causes excessive secretion of cytokines. The continuous triggering of the innate and acquired immune system, as well as the overproduction of pro-inflammatory factors, cause a severe condition in the COVID-19 patients, which is called "cytokine storm". It can lead to acute respiratory distress syndrome (ARDS) in critical patients. Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator support. Various drugs, including immunomodulatory and immunosuppressive agents (e.g., monoclonal antibodies (mAbs) and interleukin antagonists) have been utilized in clinical trials. However, the studies and clinical trials have documented diverging findings, which seem to be due to the differences in these drugs' possible mechanisms of action. These drugs' mechanism of action generally includes suppressing or modulating the immune system, preventing the development of cytokine storm via various signaling pathways, and enhancing the blood vessels' diameter in the lungs. In this review article, multiple medications from different drug families are discussed, and their possible mechanisms of action are also described.
Insights
This review examines therapeutic drugs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), focusing on their mechanisms to combat COVID-19 and prevent cytokine storms.
Area of Science:
- Virology and Immunology
- Pharmacology
- Critical Care Medicine
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, presents a major global health challenge.
- SARS-CoV-2 infection can lead to severe respiratory distress through a 'cytokine storm', a hyperinflammatory response.
- Effective treatments are crucial for reducing mortality and managing critical illness.
Purpose of the Study:
- To review various therapeutic agents investigated for COVID-19 treatment.
- To elucidate the mechanisms of action for different drug classes targeting SARS-CoV-2.
- To analyze findings from clinical trials on immunomodulatory and immunosuppressive drugs.
Main Methods:
- Literature review of scientific articles and clinical trial data.
- Analysis of drug mechanisms related to viral entry, immune response modulation, and cytokine storm pathways.
- Synthesis of information on immunomodulatory and immunosuppressive agents.
Main Results:
- SARS-CoV-2 utilizes ACE2 receptors to infect pulmonary endothelial cells, triggering cytokine release.
- Cytokine storm and ARDS are critical complications in severe COVID-19 cases.
- Various drugs, including monoclonal antibodies and interleukin antagonists, show potential but with diverging clinical outcomes due to varied mechanisms.
Conclusions:
- Understanding drug mechanisms is key to optimizing COVID-19 treatment strategies.
- Further research is needed to reconcile diverging findings and establish effective therapeutic protocols.
- Targeting immune pathways and cytokine storm is essential for managing severe COVID-19.
Related Concept Videos
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

